Mitsugu Hachisu Selected Research

Cholinergic Antagonists (Anticholinergics)

1/2016	Mini Review: Anticholinergic Activity as a Behavioral Pathology of Lewy Body Disease and Proposal of the Concept of "Anticholinergic Spectrum Disorders".
11/2015	Assessment of Cognitive Dysfunction Caused by Anticholinergic Burden in Japanese Alzheimer's Disease Patients, Using the Most Commonly Used Scales in Japan.
1/2015	Beyond the Hypothesis of Serum Anticholinergic Activity in Alzheimer's Disease: Acetylcholine Neuronal Activity Modulates Brain-Derived Neurotrophic Factor Production and Inflammation in the Brain.
1/2015	Pharmacotherapy for Neurocognitive Disorders Based on the Hypothesis of Endogenous Appearance of Anticholinergic Activity.
1/2015	Serum Anticholinergic Activity as an Index of Anticholinergic Activity Load in Alzheimer's Disease.
1/2015	Hypothesis of Endogenous Anticholinergic Activity in Alzheimer's Disease.
1/2015	Demonstrating the Role of Anticholinergic Activity in a Mood Disorder.
1/2015	Anticholinergic Activity and Schizophrenia.
1/2015	A Review of the Role of Anticholinergic Activity in Lewy Body Disease and Delirium.
1/2015	Anticholinergic Activity and Alzheimer's Disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mitsugu Hachisu Research Topics

Disease

16	Alzheimer Disease (Alzheimer's Disease) 01/2016 - 03/2010
6	Cognitive Dysfunction 01/2021 - 06/2011
6	Inflammation (Inflammations) 01/2016 - 01/2015
3	Lewy Body Disease (Lewy Body Dementia) 01/2016 - 01/2014
3	Delirium 01/2016 - 01/2015
2	Neurocognitive Disorders (Clerambault Syndrome) 11/2015 - 01/2015
2	Major Depressive Disorder (Major Depressive Disorders) 01/2015 - 01/2013
1	Chronic Disease (Chronic Diseases) 01/2021
1	Mental Disorders (Mental Disorder) 10/2018
1	Confusion (Bewilderment) 11/2015
1	Schizophrenia (Dementia Praecox) 01/2015
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2015
1	Diabetes Mellitus 01/2015
1	Factitious Disorders (Ganser Syndrome) 01/2015
1	Disease Progression 01/2015
1	Mood Disorders (Mood Disorder) 01/2015
1	Amnesia (Dissociative Amnesia) 01/2013
1	Glaucoma 01/2013
1	Parkinson Disease (Parkinson's Disease) 09/2012

Drug/Important Bio-Agent (IBA)

17	Cholinergic Antagonists (Anticholinergics)IBA 01/2016 - 03/2010
7	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2016 - 01/2013
5	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2015 - 01/2013
4	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2021 - 01/2015
3	Donepezil (Aricept)FDA LinkGeneric 01/2015 - 01/2013
2	Biomarkers (Surrogate Marker)IBA 10/2018 - 06/2011
2	CytokinesIBA 01/2016 - 01/2015
2	Cholinergic Agents (Cholinergics)IBA 01/2014 - 01/2011
1	AntibodiesIBA 01/2015
1	Choline O-Acetyltransferase (Choline Acetyltransferase)IBA 01/2015
1	Cholinesterases (Cholinesterase)IBA 01/2015
1	LipidsIBA 01/2015
1	Oxygen (Dioxygen)IBA 01/2015
1	Duloxetine Hydrochloride (Cymbalta)FDA Link 01/2015
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2015
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2015
1	Amyloidogenic ProteinsIBA 01/2015
1	Antidepressive Agents (Antidepressants)IBA 01/2013
1	Sigma-1 ReceptorIBA 01/2013
1	Antipsychotic Agents (Antipsychotics)IBA 06/2011
1	Nootropic Agents (Nootropics)IBA 03/2010

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2015 - 01/2015
1	Therapeutics 01/2015
1	Aftercare (After-Treatment) 01/2013